Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront
Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.
